EQL Pharma
55.00 SEK
-1.43 %
Less than 1K followers
EQL
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Valuation
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for EQL Pharma
P/E
Median 2019-2025
EV/S
Median 2019-2025
EV/EBIT
Median 2019-2025
P/B
Median 2019-2025
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Share price (SEK) | 12.05 | 13.40 | 35.10 | 31.00 | 37.40 | 42.30 | 71.00 |
| Shares | 29.1 | 29.1 | 29.1 | 29.1 | 29.1 | 29.1 | 29.1 |
| Market cap | 350.2 | 389.4 | 1,020.1 | 901.0 | 1,087.0 | 1,229.4 | 2,063.5 |
| Enterprise value | 328.5 | 379.3 | 994.9 | 859.8 | 1,109.2 | 1,329.0 | 2,432.7 |
| EV/S | 6.6 | 5.3 | 5.6 | 2.1 | 4.3 | 5.0 | 6.5 |
| EV/EBITDA | 97.4 | 52.0 | 86.9 | 22.1 | 26.8 | 40.7 | 36.1 |
| EV/EBIT | neg. | 120.2 | 86.9 | 22.1 | 26.8 | 40.7 | 36.1 |
| P/E | neg. | 143.9 | 98.2 | 28.4 | 34.3 | 54.2 | 48.0 |
| P/B | 4.48 | 4.81 | 11.17 | 7.29 | 7.02 | 6.92 | 9.34 |
| P/S | 7.0 | 5.4 | 5.7 | 2.2 | 4.2 | 4.7 | 5.5 |
| Dividend yield | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
| Equity ratio | 76.6 % | 65.1 % | 45.9 % | 52.0 % | 54.2 % | 47.6 % | 27.3 % |
| Gearing ratio | - | - | - | - | 43.1 % | 67.6 % | 204.3 % |